Metrics raised 1
- 7 GW Topcon cell line first revenue target: September 2026 (from prior December assumption)
Metrics cut 1
- Transformer FY27 revenue guidance: slightly below ₹600-700 crores (from analyst estimate of ₹600-700 crores)
Event Participants
Executives
3 Chiranjeev Singh Saluja (Managing Director), Nand Kishore Khandelwal (Group CFO), Vinay Rustagi (Chief Business Officer)
Analysts
13 Apoorv Bahadur (IIFL Capital), Anupam Goswami, Karan Gupta (Asit C Mehta), Ketan Jain (Avindus Park), Kunal Shah (DAM Capital), Mayur Patel (360 ONE), Nitin Arora (Axis Mutual Funds), Prakhar Porwal (Ambit Capital), Praveen Sahay (Prabhudas Lilladher/PL Capital), Raman KV (Sequent Investments), Shubham Borade (ICICI Securities), Shweta (Anand Rathi), Shyam Maheshwari (Aditya Birla Sunlife Mutual Fund)
Note: Transcript contains participant-labeling inconsistencies; analysts listed based on announced participation.
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹2,508 crores | +34% YoY; record quarter; includes consolidation of 51% stake in Transcon (1 month contribution) |
| EBITDA | ₹759 crores | +27% YoY; margin steady at 30.3% |
| Net Profit (PAT) | ₹472 crores | +53% YoY; margin 18.8% |
| Order Inflow | ₹3,011 crores | New orders secured for cells and modules in Q1; momentum driven by DCR and post-ALMM extension non-DCR demand |
| Order Book | ₹15,000 crores | Includes transformers; ~40-45% of order book scheduled for FY28 execution |
| Cell Capacity Utilization | 92% | Record utilization at operational Telangana cell plants |
| Capex (Q1) | ₹1,500 crores | ₹1,250 crores on solar (Seetharampur + Naidupeta), ₹250 crores on Transcon; majority funded by equity |
| Transcon (51% subs.) | ₹110 crores revenue; ₹18 crores PAT | EBITDA margin 27%, PAT margin 17%; only 1 month contribution post-consolidation |
| Depreciation Run-Rate (Q3/Q4 est.) | ~₹240-250 crores/quarter | Full effect from Seetharampur (commissioned) and Naidupeta (commissioning) lines |
| Revenue Mix - Cell Sales | ~24% of Q1 revenue | Order book mix: ~58% cells (spread over FY28-FY29); modules booked for next 6-9 months |
Geographic & Segment Commentary
Solar Cells & Modules (India): Revenue growth of 34% YoY driven by record cell capacity utilization (92%) and strong DCR module demand. Cell sales (~24% of revenue) remain material but management expects mix to shift structurally toward DCR module sales over next 18-24 months as 10 GW cell / 11 GW module capacity comes online. DCR order book sold out up to FY28; non-DCR orders saw influx post ALMM deadline extension to December 2026, with slightly better pricing versus last quarter.
Transformers (Transcon, 51% owned): Transcon reported revenue of ₹110 crores and PAT of ₹18 crores (both for one month post-consolidation), with EBITDA margin of 27% and PAT margin of 17%. Capacity expanding from 4 GVA to 16.25 GVA by FY28, with shift toward higher-margin HV/EHV segments and export markets (North America, Europe, Africa). Management guided revenue to "treble" from ~₹400 crores base over next 3 years, with EBITDA margins expected slightly above 15% industry-cycle average.
BESS (Battery Energy Storage Systems): Land acquired and construction started on 12 GW BESS plan (6 GW Phase 1). Technology partner for containerized solutions expected to be finalized in 2-3 months. Company is deliberately pacing expansion while awaiting government guidelines on non-tariff barriers for BESS manufacturing.
Geographic Markets: India remains dominant (DCR, PM Surya Ghar, PM Kusum). Europe viewed as "takeoff stage" — company is opening a European office and hiring sales team, positioning for India-EU FTA benefits. US: JV planned for cell manufacturing, with location finalization underway; US MIP proposal makes US manufacturing compelling.
Company-Specific & Strategic Commentary
Capacity Expansion: 5.6 GW fully automated module plant at Seetharampur operational; 7 GW Topcon cell line (Naidupeta) in advanced commissioning with trial runs starting August 2026. First revenue from new cell line targeted for September; 50-60% utilization by November; ~70% utilization targeted by March quarter. Ingot-wafer lines also underway.
Backward Integration & Operating Leverage: Management expects significant operating leverage as new cell and transformer capacities come online, citing per-gigawatt manpower cost ~40% lower at Seetharampur versus legacy lines. Company continuing backward integration into ingot-wafer to protect margins.
US Expansion: JV for US cell manufacturing in progress — location finalization has been cautious given policy regime; with US minimum import price proposal (~$22 for cells), US manufacturing economics are now compelling. Output expected in 24-30 months.
Europe Entry: Advanced stages of opening European office; India-EU FTA (final stages of negotiation) would make Indian modules competitive on par with domestic European modules; export-led entry preferred over local manufacturing initially.
Technology Roadmap: Company producing G12R Topcon cells and zero-busbar cells; R&D focused on TBC (back contact) and tandem cell technologies for next 5-10 year horizon.
Capital Allocation: Enabling resolution for fund-raising approved; management confirmed no concrete primary capital raise plans in near term. Equity-funded capex limits finance cost increase.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| EBITDA Margin | 29-30% ± 100-150 bps (ongoing) | Management confident of protecting industry-leading margins through DCR mix shift, operating leverage from new capacity, and backward integration |
| 7 GW Topcon Cell Line Ramp | First revenue Sept 2026; 50-60% utilization by Nov 2026; ~70% by Q4 FY27 | Commissioning in advanced stages; trial runs this month; ramp-up typical for new cell capacities |
| PM Kusum Installations | 6-8+ GW AC over next 9 months (deadline March 2027) | Government-enforced deadline driving step-up; DC equivalent ~8-10 GW; blended DC overloading 1.2-1.25x |
| PM Surya Ghar Demand | 1.2-1.3 GW monthly average over next 9 months | Momentum strong; scheme concluding March 2027 with Surya Ghar 2.0 anticipated |
| Transformer (Transcon) Revenue | >3x from ₹400 crores base over next 3 years | Capacity ramp 4→16.25 GVA; HV/EHV mix and exports as growth levers; near-term ramp slower due to certification timelines |
| Depreciation | ~₹240-250 crores/quarter by Q3/Q4 FY27 | Full effect of Seetharampur and Naidupeta lines |
| DCR vs Cell Mix | Shift toward DCR modules over 18-24 months | 50:50 internal/external cell split to skew toward internal consumption as DCR demand scales |
Risks & Constraints
| Risk | Context |
|---|---|
| Non-DCR Market Unprofitability | Management acknowledged non-DCR module business is "not profitable as we speak" — ~200+ GW module capacity vs ~30 GW NDCR demand creates severe oversupply; margin pressure will persist; company leveraging extended ALMM deadline (December 2026) to clear module capacity profitably |
| Industry Consolidation | Smaller non-integrated module manufacturers shutting down; margins at module level "almost completely vanished" with profitability shifted upstream to cells; consolidation expected to favor large integrated players but creates near-term pricing volatility |
| Grid & Transmission Constraints | Rising solar penetration creates steeper duck curve; government pushing BESS mandates. Mitigation: storage arbitrage economics improving (₹7-8/kWh peak spread), ~20 GWh storage addition expected this year, 40-50 GWh pumped storage by FY29, distributed solar now ~40% of market |
| Trade Policy Uncertainty | US MIP proposal impacts export strategy; EU FTA finalization pending; management monitoring regulatory regimes before committing capital (US JV location, EU plant decision) |
| Commodity Price Inflation | Ongoing wars and shifting trade flows create input cost volatility; partially mitigated by dollar-based contracts and variable-cost pass-through in cell pricing (wafer, silver, FX) |
| Capacity Ramp Execution | New 7 GW cell line and transformer capacity ramp involves certification and type-testing timelines; near-term transformer revenue ramp expected slower than market hopes |
Q&A Highlights
PM Kusum & Rooftop Demand Outlook
- Question: What DC overloading assumption to use for PM Kusum demand? What is quarterly demand outlook for these segments? (Apoorv Bahadur, IIFL Capital)
- Answer: Kusum B overloading is ~1x (pumps); Kusum C projects (2-10 MW) overload at 1.3-1.5x; blended ~1.2-1.25x. Installations for next 9 months: Kusum 6-8+ GW AC, Surya Ghar 1.2-1.3 GW monthly average — combined ~23-24 GW DC demand. Government imposed March 2027 deadline for all ongoing Kusum projects. Remaining demand to come from C&I segment as ALMM requirement kicks in from January 2027. (Vinay Rustagi, CBO)
Margin Trajectory & DCR Mix
- Question: With cell sales at ~24% of revenue and ~58% of order book, how should margins evolve over next 15-18 months as mix improves? (Kunal Shah, DAM Capital; Nitin Arora, Axis Mutual Funds)
- Answer: Management confident of protecting margins at 29-30% ± 100-150 bps. Drivers: new 7 GW cell line operating leverage, transformer business margins, DCR mix shift, and backward integration (ingot-wafer). Order book currently carries margins comparable to current delivery levels. DCR order book sold out only for FY28, with C&I clients already booking FY28 capacity — demand is being pulled forward, not deferred. (Chiranjeev Singh Saluja, MD)
Transformer Business Ramp
- Question: What revenue ramp-up trajectory for transformer business in FY27-FY28? (Nitin Arora, Axis Mutual Funds)
- Answer: Initial ramp post-capacity expansion is slower due to certification and type-testing timelines. Revenue outlook slightly below analyst estimate of ₹600-700 crores for FY27; over next 3 years, revenue expected to more than triple from ₹400 crores base. Industry-cycle EBITDA margins ~15%, PAT 8-10%; company expects to be slightly ahead given low-cost base and cross-synergies with Premier Energies. (Vinay Rustagi, CBO)
New Cell Line Ramp Timeline
- Question: When will new 7 GW cell capacity start contributing revenue? (Mayur Patel, 360 ONE)
- Answer: First revenue targeted from September 2026 (earlier than December assumption). Line to reach 50-60% utilization by November; ~70% utilization targeted by March quarter, implying more than 2x current cell production run-rate. (Chiranjeev Singh Saluja, MD)
Non-DCR Market Dynamics & Cell Pricing
- Question: How is module realization trending sequentially, and what is pricing outlook for cell orders? (Praveen Sahay, Prabhudas Lilladher/PL Capital)
- Answer: Non-DCR business is not profitable currently—oversupply (~200+ GW module lines vs ~60 GW total demand, of which ~30 GW DCR). Post-ALMM extension, company secured non-DCR orders at better prices vs last quarter as developers rush to commission before December. Cell pricing stable with no dilution; long-term cell contracts are variable-priced (wafer, silver, FX pass-through). Topcon cells currently for internal consumption only; monoperc cells sold externally. (Chiranjeev Singh Saluja, MD)
Expense Increase & Depreciation Run-Rate
- Question: What explains ~50% increase in other expenses and ~70% in employee costs? What is expected depreciation run-rate? (Ketan Jain, Avindus Park)
- Answer: Depreciation lower due to prior year accelerated depreciation; now on normal 5-year schedule for new cell/module lines. Quarterly depreciation expected at ₹240-250 crores in Q3/Q4 once Naidupeta line is fully commissioned. Other expenses increased ₹120→₹180 crores primarily due to Seetharampur operational costs post-capitalization (power costs in Q1 before revenue ramp in July). Employee costs reflect advance hiring for new lines (3-6 months ahead); per-gigawatt manpower costs expected ~40% lower at Seetharampur vs legacy lines. (Vinay Rustagi, CBO; Chiranjeev Singh Saluja, MD)
US Manufacturing & MIP
- Question: Given US MIP circular (cell import price ~$22), does it now make sense to set up US cell/module manufacturing? (Shyam Maheshwari, Aditya Birla Sunlife Mutual Fund)
- Answer: Company already has a JV planned for US cell manufacturing; location finalization has been slow due to policy regime uncertainty. MIP proposal makes US manufacturing economics compelling. Output expected in 24-30 months from finalization. (Chiranjeev Singh Saluja, MD)
Europe Expansion Strategy
- Question: Is Europe an export opportunity or manufacturing location? (Kunal Shah, DAM Capital)
- Answer: EU policy (Net Zero Industry Act) gives FTA-country modules same status as domestic modules; India-EU FTA in final stages. Export from India is first preference; completely open to setting up EU plant depending on demand growth and policy environment. Company is in advanced stages of opening European office with dedicated sales team; tenders already emerging (Italy large auction, France tenders, Germany expected). (Vinay Rustagi, CBO)
Industry Consolidation & Entry Barriers
- Question: With small module/cell manufacturers shutting down, how is industry shaping up? What creates sustainable competitive advantage? (Raman KV, Sequent Investments)
- Answer: Competition driven by scale, vertical integration, and technology; ALMM 2.0/3.0 will accelerate consolidation favoring large integrated players. Module-level margins have essentially vanished; profitability pool has shifted to cells and upstream. Entry barriers are capital intensity and operational expertise, not regulation. Companies with 10+ GW scale enjoy massive advantages in cost, logistics, working capital, and pricing power. (Vinay Rustagi, CBO)
Key Takeaway
Premier Energies delivered another record quarter with revenue of ₹2,508 crores (+34% YoY), EBITDA of ₹759 crores (30.3% margin), and PAT of ₹472 crores (+53% YoY), aided by strong DCR module demand, record 92% cell capacity utilization, and first-month consolidation of Transcon. Management is protecting a margin band of 29-30% ± 100-150 bps through DCR mix shift (order book sold out to FY28), operating leverage from the newly operational 5.6 GW module plant and 7 GW Topcon cell line (first revenue September, ~70% utilization by March), and backward integration into ingot-wafer. Strategic initiatives include a US cell manufacturing JV (accelerated by MIP proposal, 24-30 months to output), European market entry via office setup ahead of India-EU FTA, and 6 GW BESS Phase 1 with technology partner selection within 2-3 months. The ₹15,000 crore order book (40-45% spilling into FY28) provides revenue visibility, but near-term watch points include persistent non-DCR market unprofitability, industry consolidation among smaller module players, and potential grid transmission constraints, which management believes are mitigated by storage economics and distributed solar growth.
Transcript incomplete - no separate financial statements section provided; Q&A contains participant-labeling inconsistencies attributable to transcription errors.